azathioprin medac 25 mg tabletti, kalvopäällysteinen
medac gesellschaft für klinische spezialpräparate mbh - azathioprinum - tabletti, kalvopäällysteinen - 25 mg - atsatiopriini
azathioprin medac 50 mg tabletti, kalvopäällysteinen
medac gesellschaft für klinische spezialpräparate mbh - azathioprinum - tabletti, kalvopäällysteinen - 50 mg - atsatiopriini
mercaptopurin orion 50 mg tabletti
orion corporation - mercaptopurine monohydrate - tabletti - 50 mg - merkaptopuriini
purimmun 50 mg tabletti
2care4 generics aps - mercaptopurine monohydrate - tabletti - 50 mg - merkaptopuriini
jayempi
nova laboratories ireland limited - azathioprine - graft hylkääminen - immunosuppressantit - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.
phenoleptil vet 12.5 mg tabletti
dechra regulatory b.v. - phenobarbital - tabletti - 12.5 mg - fenobarbitaali
phenoleptil vet 50 mg tabletti
dechra regulatory b.v. - phenobarbital - tabletti - 50 mg - fenobarbitaali
kymriah
novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - muut antineoplastiset aineet - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.
ilomedin 0.1 mg/ml infuusiokonsentraatti, liuosta varten
bayer oy - iloprost trometamol - infuusiokonsentraatti, liuosta varten - 0.1 mg/ml - iloprosti
lisinopril ratiopharm 10 mg tabletti
ratiopharm gmbh - lisinopril dihydrate - tabletti - 10 mg - lisinopriili